نتایج جستجو برای: interferon β 1a
تعداد نتایج: 272193 فیلتر نتایج به سال:
OBJECTIVE To describe detailed MRI results from 2 head-to-head phase III trials, Comparison of Alemtuzumab and Rebif Efficacy in Multiple Sclerosis Study I (CARE-MS I; NCT00530348) and Study II (CARE-MS II; NCT00548405), of alemtuzumab vs subcutaneous interferon β-1a (SC IFN-β-1a) in patients with active relapsing-remitting multiple sclerosis (RRMS). METHODS The impact of alemtuzumab 12 mg vs...
OBJECTIVE To report the long-term safety and efficacy results from CAMMS223 comparing alemtuzumab with interferon β-1a in early, active relapsing-remitting multiple sclerosis (RRMS). What are the long-term effects of alemtuzumab treatment, received 36 to 48 months previously, on relapse and disability in early, active RRMS? This study provides evidence of the effectiveness of alemtuzumab in red...
A new formulation (NF) of subcutaneous (sc) interferon (IFN) β-1a was developed in an attempt to improve injection tolerability and immunogenicity. We compared antiviral and IFNβ-stimulated gene (ISG) activities of IFNβ-1a sc NF with IFNβ-1a sc original formulation and IFNβ-1b sc. When equivalent unit amounts were compared, the IFNβ formulations demonstrated similar antiviral activity and induc...
hla-g is normally expressed on human trophoblast cells. it is a non-classical mhc molecule class i b. the role of hla-g in diabetic type 1 is not known. we investigated the role of ifn-β in induction hla-g expression on the monocyte derived dendritic cells (dc) in diabetes type 1. treatment of dendritic cell with ifn-β in vitro from diabetic patients (n=20) and normal subjects (n=20) resulted t...
Background No evidence of disease activity (NEDA; defined as no 12-week confirmed disability progression, no protocol-defined relapses, no new/enlarging T2 lesions and no T1 gadolinium-enhancing lesions) using a fixed-study entry baseline is commonly used as a treatment outcome in multiple sclerosis (MS). Objective The objective of this paper is to assess the effect of ocrelizumab on NEDA usi...
مقدمه: اینترفرون بتا (ifn-β یا interferon beta) اولین داروی تأیید شده برای درمان مولتیپل اسکلروز (ms یا multiple sclerosis) است. برخی از بیماران مبتلا به ms تحت درمان با ifn-β در برابر این دارو آنتی بادی ایجاد می کنند. آنتی بادی های ضد ifn-β می توانند کارایی بالینی و فعالیت زیستی آن را کاهش دهند. هدف از این مطالعه، طراحی روش elisa برای اندازه گیری آنتی بادی های سرمی ضد اینترفرون در بیماران مبتل...
background: it has been reported that liver function alterations occur in 8–38% of patients with relapsing-remitting multiple sclerosis (rrms) treated with interferon-beta in controlled clinical trials or in prospective but non-controlled studies. we report herein a case of symptomatic liver dysfunction associated with two-year-period of regular interferon-beta-1a (avonex®) intramuscular inject...
Introduction: Based on data from recent trials, peginterferon and ribavirin combination therapy is the standard of care in treating patients with chronic HCV infection, but because of high costs, many patients may deprive from treatment. Methods: We conducted a clinical trial on HCV patients in Yazd in gastroenterology clinic. Thirty patients received conventional subcutaneous interferon alf...
نمودار تعداد نتایج جستجو در هر سال
با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید